Your browser doesn't support javascript.
loading
Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study.
Ishigo, Tomoyuki; Fujii, Satoshi; Ibe, Yuta; Aigami, Tomohiro; Nakano, Keita; Fukudo, Masahide; Yoshida, Hiroaki; Tanaka, Hiroaki; Ebihara, Fumiya; Maruyama, Takumi; Hamada, Yukihiro; Suzuki, Ayako; Fujihara, Hisato; Yamaguchi, Fumihiro; Samura, Masaru; Nagumo, Fumio; Komatsu, Toshiaki; Tomizawa, Atsushi; Takuma, Akitoshi; Chiba, Hiroaki; Nishi, Yoshifumi; Enoki, Yuki; Taguchi, Kazuaki; Matsumoto, Kazuaki.
Afiliação
  • Ishigo T; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Fujii S; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Ibe Y; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Aigami T; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Nakano K; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Fukudo M; Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
  • Yoshida H; Department of Pharmacy, Kyorin University Hospital, Mitaka, Japan.
  • Tanaka H; Department of Pharmacy, Kyorin University Hospital, Mitaka, Japan.
  • Ebihara F; Department of Pharmacy, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Maruyama T; Department of Pharmacy, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Hamada Y; Department of Pharmacy, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Suzuki A; Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Fujihara H; Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Yamaguchi F; Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Samura M; Department of Pharmacy, Yokohama General Hospital, Yokohama, Japan; Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Nagumo F; Department of Pharmacy, Yokohama General Hospital, Yokohama, Japan.
  • Komatsu T; Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan.
  • Tomizawa A; Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan.
  • Takuma A; Department of Pharmacy, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Chiba H; Department of Pharmacy, Tohoku Kosai Hospital, Sendai, Japan.
  • Nishi Y; Center for Pharmacist Education, School of Pharmacy, Nihon University, Funabashi, Japan.
  • Enoki Y; Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Taguchi K; Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Matsumoto K; Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan. Electronic address: matsumoto-kz@pha.keio.ac.jp.
J Infect Chemother ; 30(4): 329-336, 2024 Apr.
Article em En | MEDLINE | ID: mdl-37925103
ABSTRACT

INTRODUCTION:

In therapeutic drug monitoring (TDM) of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to the clinical efficacy and toxicity. Therefore, herein, we examined the factors associated with achieving the target AUC at follow-up and developed a decision flowchart for achieving the target AUC in critically ill patients.

METHODS:

This multicenter retrospective observational study was conducted at eight hospitals. We retrospectively analyzed data from patients who had received VCM in the intensive care unit from January 2020 to December 2022. Decision-tree (DT) analysis was performed using factors with p < 0.1 in univariate analysis as the independent variables. Case data were split up to two times, and four subgroups were included. The primary endpoint was achieving the target AUC at the follow-up TDM (AUCfollow-up) and target AUCfollow-up achievement was defined as an AUC of 400-600 µg‧h/mL. The initial AUC values were calculated with the 2-point concentrations (peak and trough) using the Bayesian estimation software Practical AUC-guided TDM (PAT).

RESULTS:

Among 70 patients (median age [interquartile range], 66 [56, 79] years; 50 % women), the AUCfollow-up was achieved in 70 % (49/70). Three factors were selected for the decision flow chart predicted AUCfollow-up of 400-600 µg‧h/mL, dosing at 12-h intervals, and CCr of 130 mL/min/1.73 m2 or higher; the accuracy was adequate (92 %, R2 0.52).

CONCLUSION:

We successfully identified the factors associated with achieving the target AUC of VCM at follow-up TDM and developed a simple-to-use DT model. However, the validity of the findings needs to be evaluated.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vancomicina / Estado Terminal Limite: Aged / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vancomicina / Estado Terminal Limite: Aged / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: J Infect Chemother Assunto da revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão